The primary goal ( cardiovascular death , nonfatal myocardial infarction and nonfatal CMP ) occurred in @ % ( @ ) patients treated with saxagliptin and in @ % ( @ ) patients treated with placebo ( HR @ , p < @ for non inferiority ) .